66
Participants
Start Date
March 20, 2019
Primary Completion Date
June 6, 2022
Study Completion Date
December 9, 2022
Mepolizumab 300 mg
Mepolizumab 300 mg subcutaneous injection
Mepolizumab 100 mg
Mepolizumab 100 mg subcutaneous injection
Placebo
Saline subcutaneous injection
University of North Carolina at Chapel Hill, Chapel Hill
MNGI Digestive Health, P.A., Minneapolis
Northwestern University, Chicago
University of Utah, Salt Lake City
Collaborators (1)
GlaxoSmithKline
INDUSTRY
University of Utah
OTHER
Northwestern University
OTHER
MNGI Digestive Health, P.A.
OTHER
University of North Carolina, Chapel Hill
OTHER